| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C22orf28 |
| Uniprot No | Q9Y3I0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-505aa |
| 氨基酸序列 | MSRSYNDELQ FLEKINKNCW RIKKGFVPNM QVEGVFYVND ALEKLMFEEL RNACRGGGVG GFLPAMKQIG NVAALPGIVH RSIGLPDVHS GYGFAIGNMA AFDMNDPEAV VSPGGVGFDI NCGVRLLRTN LDESDVQPVK EQLAQAMFDH IPVGVGSKGV IPMNAKDLEE ALEMGVDWSL REGYAWAEDK EHCEEYGRML QADPNKVSAR AKKRGLPQLG TLGAGNHYAE IQVVDEIFNE YAAKKMGIDH KGQVCVMIHS GSRGLGHQVA TDALVAMEKA MKRDKIIVND RQLACARIAS PEGQDYLKGM AAAGNYAWVN RSSMTFLTRQ AFAKVFNTTP DDLDLHVIYD VSHNIAKVEQ HVVDGKERTL LVHRKGSTRA FPPHHPLIAV DYQLTGQPVL IGGTMGTCSY VLTGTEQGMT ETFGTTCHGA GRALSRAKSR RNLDFQDVLD KLADMGIAIR VASPKLVMEE APESYKNVTD VVNTCHDAGI SKKAIKLRPI AVIKG |
| 预测分子量 | 55,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C22orf28重组蛋白的假设性参考文献示例(仅供参考，实际文献需通过学术数据库查询)：
1. **标题**：*Cloning and Expression of Recombinant C22orf28 Protein in Escherichia coli*
**作者**：Smith A, et al.
**摘要**：该研究成功在大肠杆菌中克隆并表达了C22orf28重组蛋白，优化了表达条件并通过亲和层析纯化。初步功能实验表明，该蛋白可能参与细胞周期调控。
2. **标题**：*Functional Characterization of C22orf28 Using Recombinant Protein Technology*
**作者**：Johnson B, et al.
**摘要**：通过哺乳动物细胞表达系统制备C22orf28重组蛋白，发现其与MAPK信号通路中的激酶相互作用，提示其在细胞应激反应中的潜在作用。
3. **标题**：*Structural Analysis of Recombinant C22orf28 and Its Putative Role in DNA Repair*
**作者**：Lee C, et al.
**摘要**：利用重组表达的C22orf28蛋白进行X射线晶体学分析，鉴定出N端DNA结合结构域，并发现其与DNA损伤修复相关蛋白存在共定位现象。
4. **标题**：*C22orf28 Recombinant Protein as a Potential Biomarker in Cancer Studies*
**作者**：Wang D, et al.
**摘要**：通过重组蛋白制备抗体，检测多种肿瘤组织中C22orf28的表达水平，发现其高表达与乳腺癌患者预后不良显著相关。
**注**：以上为模拟文献，实际研究中请通过PubMed、Web of Science等平台检索最新成果。若C22orf28功能尚不明确，建议扩大关键词范围(如结合染色体22相关疾病或通路)。
**Background of C22orf28 Recombinant Protein**
C22orf28 (Chromosome 22 Open Reading Frame 28) is a protein-coding gene located on human chromosome 22. While its biological functions remain poorly characterized, emerging studies suggest potential roles in cellular processes such as transcriptional regulation, protein interactions, or stress responses. The gene is evolutionarily conserved across vertebrates, implying functional importance, but its specific mechanisms and pathways are not yet fully elucidated.
The C22orf28 protein is predicted to contain intrinsically disordered regions, which may facilitate dynamic interactions with other biomolecules. Its expression has been detected in various tissues, including the brain, testis, and immune cells, though at relatively low levels. Dysregulation of C22orf28 has been tentatively linked to diseases such as gliomas, Alzheimer’s disease, and certain cancers, though evidence remains preliminary. For example, altered expression in tumor tissues suggests a possible, yet unconfirmed, role in oncogenesis or tumor suppression.
Recombinant C22orf28 protein is engineered in vitro using expression systems (e.g., bacterial, mammalian) to enable functional studies. Its production allows researchers to investigate protein structure, post-translational modifications, binding partners, and cellular localization. Antibodies generated against recombinant C22orf28 aid in detecting endogenous protein levels, facilitating disease biomarker research.
Current research focuses on clarifying its molecular interactions, such as potential involvement in RNA processing or chromatin remodeling, based on sequence motifs and domain predictions. However, the lack of comprehensive in vivo data highlights the need for further exploration. Recombinant C22orf28 serves as a critical tool to bridge this knowledge gap, offering insights into its physiological and pathological significance.
In summary, C22orf28 represents an understudied gene with emerging relevance in human health, and recombinant protein technology remains pivotal in unraveling its biological and clinical implications.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
